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Abstract 
Chemokines are the principal regulators of 
leukocyte migration and are essential for initiation 
and maintenance of inflammation. Atypical 
chemokine receptor 2 (ACKR2) binds and 
scavenges proinflammatory CC-chemokines, 
regulates cutaneous T-cell positioning, and limits 
the spread of inflammation in vivo. Altered 
ACKR2 function has been implicated in several 
inflammatory disorders, including psoriasis, a 
common and debilitating T cell–driven disorder 
characterized by thick erythematous skin plaques. 
ACKR2 expression is abnormal in psoriatic skin, 
with decreased expression correlating with 
recruitment of T cells into the epidermis and 
increased inflammation. However, the molecular 
mechanisms that govern ACKR2 expression are 
not known. Here, we identified specific psoriasis-
associated microRNAs (miRs) that bind ACKR2, 
inhibit its expression, and are active in primary 
cultures of human cutaneous cells. Using both in 
silico and in vitro approaches, we show that miR-
146b and miR-10b directly bind the ACKR2 3’-
UTR and reduce expression of ACKR2 transcript 
and protein in keratinocytes and lymphatic 
endothelial cells, respectively. Moreover, we 
demonstrate that ACKR2 expression is further 
downregulated upon cell trauma, an important 
trigger for the development of new plaques in 
many psoriasis patients (the Koebner 
phenomenon). We found that tensile cell stress 
leads to rapid ACKR2 downregulation and 
concurrent miR-146b upregulation. Together, we 
provide, for the first time, evidence for epigenetic 
regulation of an atypical chemokine receptor. We 
propose a mechanism by which cell trauma and 
miRs coordinately exacerbate inflammation via 
downregulation of ACKR2 expression and provide 
a putative mechanistic explanation for the Koebner 
phenomenon in psoriasis.  
 
 
Introduction 
Chemokines are members of a large 
family of chemotactic cytokines that are the 
primary in vivo regulators of leukocyte migration. 
Chemokines are central to the pathogenesis of 
inflammatory diseases(1,2) and interact with 
leukocytes through members of the 7-
transmembrane spanning family of G-protein 
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coupled receptors(3) to orchestrate the recruitment 
of inflammatory cells into, and within, tissues. 
Chemokines and their receptors are broadly 
categorised as being either inflammatory or 
homeostatic according to the in vivo contexts in 
which they function. Importantly, in addition to 
the classical signalling chemokine receptors, there 
exists a subfamily of chemokine-binding 7-
transmembrane spanning molecules which are 
referred to as atypical chemokine receptors 
(ACKRs). The ACKRs are promiscuous in their 
ligand binding, tend to be expressed on stromal 
cells and are unable to mediate typical chemokine-
induced signalling responses following ligand 
binding(4-6). We have a particular interest in one 
of these; Atypical Chemokine Receptor 2 
(ACKR2; previously known as D6), which is a 
high-affinity receptor for multiple inflammatory 
CC-chemokines(5,7,8). ACKR2 does not mount 
classical signalling responses following ligand 
binding(9) but internalises ligands and targets 
them for intracellular degradation(10,11). Thus 
ACKR2 functions as a scavenger of pro-
infammatory chemokines and its dysfunction has 
been implicated in numerous inflammatory 
diseases(6). In addition, ACKR2 is involved in 
regulating a range of inflammation-dependent 
developmental processes(12,13).  
ACKR2 expression is elevated in many 
human inflammatory conditions including 
rheumatoid arthritis(14), systemic sclerosis(15) 
and psoriasis(16). Psoriasis is a common systemic 
inflammatory disease, with profound effects 
associated with both excess morbidity and 
mortality(17,18). Psoriasis is typically 
characterised by clearly demarcated thick 
erythematous skin plaques with white adherent 
scales surrounded by extensive areas of apparently 
normal looking (unaffected) skin. Psoriatic 
plaques tend to preferentially develop in areas 
undergoing repeated trauma such as the skin on 
the  elbows and knees(19). Additionally, the 
Koebner phenomenon is frequently reported in 
patients with psoriasis, whereby relatively simple 
skin trauma, of unaffected skin, leads to the rapid 
development of psoriatic plaques in the vicinity of 
the preceding trauma(20). 
In healthy skin, ACKR2 is primarily 
expressed by dermal lymphatic endothelial cells 
and keratinocytes. ACKR2 expression in these 
cells helps to compartmentalise tissue 
inflammatory responses to insult and infection by 
controlling the position of inflammatory 
leukocytes(21-23). We have recently shown that 
the spread of psoriasiform inflammation to 
unaffected cutaneous sites is restricted by selective 
up-regulation of cutaneous ACKR2 in the 
unaffected epidermis. At these sites, high ACKR2 
expression in keratinocytes limits local chemokine 
activity and suppresses entry of T-cells into the 
epidermis thereby protecting against the 
development of plaques in uninvolved skin. In 
contrast, skin in which ACKR2 expression is 
relatively reduced is associated with enhanced 
inflammatory chemokine activity, increased 
numbers of infiltrating T-cell in the epidermis and 
the emergence of inflammatory plaques(24). The 
factors that trigger nascent plaque development in 
psoriasis are not well understood, although our 
previous data suggest that one such factor includes 
simple skin trauma, which induces down-
regulation of epidermal ACKR2(16).  
Despite the importance of epidermal 
ACKR2 in regulating psoriasiform inflammation, 
and its transcriptional response to cutaneous 
trauma, the molecular mechanisms by which 
ACKR2 expression is regulated in keratinocytes 
are not understood. Here, by utilising a 
combination of in silico and in vitro approaches, 
we identify two psoriasis-associated microRNAs 
that are upregulated by trauma in primary cultures 
of human keratinocytes. We show that the 
identified microRNAs bind the ACKR2 3’UTR 
resulting in decreased expression at the transcript 
and protein level. As such, this is the first 
demonstration of known disease-associated 
miRNAs regulating atypical chemokine receptor 
expression and thereby modulating positioning of 
inflammatory leukocytes within the skin. 
Importantly, our study highlights a novel 
molecular mechanism by which trauma leads to 
the development of new plaques in psoriasis (the 
Koebner phenomenon).  
 
Results 
Three psoriasis-associated microRNAs 
are predicted to bind the ACKR2 3’-UTR: 
MicroRNAs have emerged as the most abundant 
class of gene regulators, and have been implicated 
in a range of inflammatory disease processes. 
They predominantly act as negative regulators of 
gene expression at a post-transcriptional level(25). 
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MicroRNAs bind their mRNA target 3’-
utranslated region (3’-UTR) which leads to mRNA 
degradation. Typically, one microRNA binds 
multiple mRNA targets, and the same mRNA 3’-
UTR can be targeted by numerous microRNAs; 
this promiscuity introduces a significant degree of 
complexity in microRNA/target interactions and 
subsequent regulation of gene expression(26). 
Recent studies have shown that many microRNAs 
are differentially expressed in psoriasis, with a 
large number being significantly overexpressed in 
the psoriatic plaques(27). Given their abundance 
as negative regulators of gene expression, 
microRNAs are thus plausible regulators of 
ACKR2 expression. Accordingly, we used the 
bioinformatics database TargetScan to identify 
possible microRNA targets on the ACKR2 3’-
UTR. As ACKR2 is present throughout mammals, 
results were filtered such that only microRNAs 
that are broadly conserved amongst vertebrates 
would be identified, in order to increase the 
likelihood of identified microRNA species being 
biologically relevant. Using this search strategy 16 
microRNAs were identified that were both 1) 
predicted to bind the 3’-UTR of human ACKR2, 
and 2) broadly conserved amongst vertebrates (the 
top 10 hits are shown in Figure 1a). To further 
focus in on those microRNAs of relevance to 
psoriasis pathogenesis, we compared the list of 
microRNAs that are predicted to bind the 3’-UTR 
of ACKR2 with microRNAs previously shown to 
be differentially expressed in psoriatic plaques, 
where ACKR2 expression is reduced relative to 
the surrounding tissue(16). In this way, we 
identified 3 microRNAs that were present in both 
lists; miR-10, miR-146 and miR-203. Notably, 
each of these miRNAs had a particularly high in 
silico likelihood of regulating ACKR2 (Figure 
1a,1b). Additionally, these 3 microRNAs have 
each been shown to play roles in skin homeostasis 
and inflammation(28-30). They are thus plausible 
epigenetic regulators of ACKR2 expression and 
were selected for further evaluation. 
 
miR-146b and miR-10b reduce the 
expression of ACKR2 mRNA in primary 
human KC and LEC respectively: Keratinocytes 
(KC) and lymphatic endothelial cells (LEC) are 
the main ACKR2 expressing cells in skin(16,31). 
In order to ensure that microRNAs could be 
successfully transfected into primary KC, cells 
were transfected with miR-146b (most strongly 
upregulated miRNA in psoriatic plaques; Figure 
1A) for 24h and the expression of 2 IFN-induced 
genes known to be downregulated by miR-146b 
(IRAK1 and TRAF6) determined by Q-PCR 
(Figure 2a). The data show a clear ability of miR-
146b to downregulate levels of both transcripts 
thus demonstrating that microRNA could be 
successfully delivered into the cytoplasm of KC. 
Primary KCs from at least two separate healthy 
donors were used for all subsequent experiments. 
Transfection of KC with miR-146b significantly 
suppressed ACKR2 mRNA expression however 
miR-10b and miR-203 had no significant effects 
on ACKR2 transcript levels (Figure 2b).  
miR-146a and b are differentially 
expressed in psoriasis, suggesting non-redundant 
roles in this context(27), although our in silico 
analyses predicted that miR-146a and miR-146b 
both bind the ACKR2 3’-UTR (Figure 1a). In 
order to determine whether any differences exist 
between miR-146a and miR-146b in the regulation 
of ACKR2 expression the two were directly 
compared (Figure 2c). Both miR-146a and miR-
146b mediated a similar reduction in ACKR2 
mRNA expression in KC after 24 hours with no 
significant differences between the two variants. 
Thus, both miR-146a and miR-146b down-
regulate ACKR2 transcript levels in KC. Next the 
3 microRNAs were transfected into primary 
healthy human dermal LECs, which also express 
high levels of ACKR2. Only miR-10b 
significantly reduced ACKR2 mRNA expression 
in LECs (Figure 2d). Thus these data demonstrate 
that psoriasis-associated micro-RNAs are capable 
of regulating ACKR2 expression in keratinocytes 
and lymphatic endothelial cells. 
 
miR-146b/miR-10b bind directly to the 
ACKR2 3’-UTR: To determine whether miR-
146b and miR-10b reduce ACKR2 transcripts 
through direct interaction with the ACKR2 3’-
UTR, the 3’-UTR of ACKR2 was cloned into a 
dual luciferase reporter vector (the pmiRGLO 
vector). The ACKR2 3’-UTR containing putative 
miRNA target sites, were inserted immediately 3’ 
of a PGK promoter-driven Firefly luciferase gene 
to evaluate ACKR2 3’-UTR dependent microRNA 
interactions on transcription. This construct was 
transfected into HEK293 cells and stable clones 
selected. These clones were then confirmed as 
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being amenable to microRNA transfection by 
assessing IRAK1 expression which was 
significantly reduced following miR146b 
transfection (Figure 3a). Having demonstrated that 
HEK cells could be transfected with functional 
microRNAs of interest, we next determined 
whether miR-10 and miR-146b transfection 
modulated luciferase activity (Figure 3b). Both 
miR-10 and miR-146b transfection significantly 
downregulated luciferase activity in HEK cells, 
although dual transfection with both miR did not 
result in an additive decrease. Thus, both miR-10 
and miR-146b can mediate a decrease in transcript 
levels through direct interactions with the ACKR2 
3’-UTR.  
 
miR-146b transfection of KC and miR-
10b transfection of LEC reduced ACKR2 
protein expression: Next we determined the 
effect of miR-146b on ACKR2 protein expression 
and distribution in primary KC and LECs. For 
reasons that are not immediately obvious, we have 
been unable to successfully apply our functional 
ACKR2 assay(31) to primary keratinocytes. We 
have therefore relied on immunofluorescence 
analysis to measure ACKR2 protein levels. Fully 
confluent human KC monolayers (Figure 4a with 
isotype control shown in 4b) were transfected with 
miR-146b for 48 hours and ACKR2 protein 
expression determined by immunocytochemistry. 
Bright green punctate cytoplasmic staining, typical 
of ACKR2 expression in other cell types(11,32), 
was observed in KC transfected with scrambled 
miR control (Figure 4c). This staining was more 
marked in the peri-nuclear region and often in an 
asymmetrical fashion in keeping with higher 
ACKR2 levels in the endoplasmic reticulum. This 
immunofluorescence staining pattern is as 
expected and we have previously published that 
the majority of ACKR2 protein is found within 
intracellular vesicles that traffic to, and from, the 
cell surface(11,32). In contrast, when monolayers 
of KC were transfected with miR-146b, cells 
exhibited a loss of ACKR2 staining throughout the 
cytoplasm, although the peri-nuclear staining was 
still evident (Figure 4d). 
To investigate the effect of miR-10b on 
ACKR2 expression in human LECs, LECs that 
had been grown as confluent monolayers were 
transfected with miR-10b and ACKR2 protein 
expression determined, by immunofluorescence, 
after 48 hours (Figure 5a with isotype control 
shown in 5b). In keeping with the known 
difference in ACKR2 transcript level, the level of 
ACKR2 protein staining was less intense in LEC 
compared to KCs. The granular staining in LEC 
was again more marked to one side of the peri-
nuclear region (akin to what was observed in KC), 
which became especially apparent at higher 
magnification (Figure 5c). Importantly, ACKR2 
staining was more pronounced and more granular 
in scrambled miR control transfected LECs, 
compared to miR-10b transfected LECs, in which 
staining was not higher than background auto-
fluorescence (Figure 5b,d).  
Taken together, immunofluorescent 
staining of cultured cell monolayers demonstrated 
that transfection with miR-146b in KC and miR-
10b in LEC led to a reduction in ACKR2 staining 
in both cell types by 48 hours.   
 
Tensile cell trauma of cytokine-treated 
KC leads to a rapid reduction in ACKR2 
mRNA expression: Next, we examined the 
possible relevance of our finding for cutaneous 
inflammatory responses such as those typical of 
psoriasis. Psoriatic patients have elevated 
cutaneous ACKR2 expression in unaffected skin, 
which mouse models suggest may protect from 
further lesion development(24). Superficial trauma 
of unaffected skin in psoriatic patients can trigger 
psoriatic plaque development (Koebnerisation) 
concurrent with ACKR2 expression 
downregulation(16,33,34). This phenomenon is a 
feature of many psoriatic patients, where lesions 
have a particular predilection for sites that undergo 
repeated stretching in daily life (e.g. knees, 
elbows, skin folds)(20). Thus, we wanted to 
determine if tensile trauma downregulated 
ACKR2 in cultured keratinocytes in a cell-
autonomous manner, and if this correlated with 
increased miR-146 activity. In order to specifically 
determine the effect of tensile cell trauma on 
ACKR2 expression, a reductionist in vitro model 
was developed. The model developed was based 
on the FlexCell™ International FX5000 machine, 
whereby primary human cells were grown on 
silicone membranes. The membrane was 
subsequently subjected to repeated bi-axial 
cyclical tension in vitro, with a pre-determined 
degree of tension, stretch wave-form, and cycle 
number (this model is summarised in 
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Supplementary Figure S1). Neither KCs nor LECs 
adhered to uncoated silicone, and so KC were 
grown on Collagen I coated silicone while LECs 
were grown on Fibronectin coated silicone. This 
was found to be associated with stable cell 
attachment over a 12-hour stretch cycle for each 
cell type. 
To examine the effect of tensile trauma on 
KC ACKR2 expression, confluent KC monolayers 
were subjected to stretching for 12h during which 
the membrane was stretched by 15% every 0.8 
seconds (0.8Hz), which is not atypical for skin 
sites such as elbows that are exposed to daily 
repeated stretching. Cells were rested for a further 
12h before lysis to enable gene expression and 
ACKR2 expression determined by QPCR. The 
data obtained (Figure 6a) showed that stretching of 
non-inflamed KC did not result in altered ACKR2 
expression. However, these primary human cells 
are derived from healthy donors and are grown in 
the absence of typical psoriasis-associated factors. 
Psoriasis patients have markedly elevated T-cell 
cytokines, including IFNJ, that correlate with 
elevated ACKR2 in unaffected skin(16,24). 
Therefore, in order to better model human 
psoriasis, where KCs exist in the context of 
systemically elevated T-cell cytokines, KCs were 
treated with either tissue culture supernatant from 
activated human T-cells or recombinant IFNJ 
(both of which upregulate ACKR2 
expression(16,24)) and then exposed to tensile 
stress for 12h at 0.8Hz. In contrast to non-treated 
KC (Figure 6a), tensile trauma of KC pre-treated 
with T-cell supernatants, led to a significant 
decrease in ACKR2 expression (Figure 6b). This 
was also the case for IFNJ pre-treated KC, 
suggesting that KC with elevated ACKR2 levels, 
such as those found in psoriasis patients, display 
tensile stress-induced downregulation of 
expression. Interestingly, treatment of the T-cell 
supernatant with IFNJ neutralising antibodies did 
not diminish this effect, suggesting that soluble T-
cell products other than IFNJ can mediate the 
observed effect (Figure 6b). In contrast to KC, 
there was no effect on ACKR2 expression upon 
flexing of LECs that were stimulated with T-cell 
supernatant (Figure 6c). Thus, the response of 
inflamed KC and LEC to tensile stress appears to 
be different, even when cells have been similarly 
pre-treated. 
To determine whether there was a possible 
link between these observations and alterations in 
miR-146b expression, miR-146a/b expression 
levels were quantified by QPCR in inflamed KCs. 
Both miR-146a and miR-146b were upregulated in 
KC that had been treated with tissue culture 
supernatant from activated human T-cells, 
compared to resting non-inflamed KC (Figure 6d, 
grey bars). Importantly, when these cells were 
subjected to tensile trauma, this effect was 
dramatically amplified; there was an over 100-fold 
induction of miR-146a and a lesser (albeit 
significant) induction of miR-146b (Figure 6d, 
black bars). A similar observation was found for 
KC pre-treated with recombinant IFNJ and then 
subjected to stretching, although in this case miR-
146b was more strongly induced than miR-146a 
(Figure 6e). Taken together, these data suggest 
that KC exposed to psoriasis-associated T-cell 
cytokines markedly upregulate miR-146a/b 
expression concurrent with ACKR2 
downregulation upon stretching and provides a 
putative mechanistic link that explains the 
Koebner phenomenon in psoriasis.  
 
Discussion 
The atypical chemokine receptor ACKR2 
is expressed in barrier tissues, including the skin, 
and functions as a high-capacity scavenger of pro-
inflammatory CC-chemokines. In vivo, and 
specifically in the context of psoriasiform 
inflammation, we have shown that ACKR2 
restricts T-cell entry into the epidermis and limits 
inflammation. Additionally, ACKR2 expression is 
deficient in psoriatic plaques in humans, which 
may enable uncontrolled inflammation and 
thereby plaque formation. The mechanism by 
which ACKR2 downregulation occurs has, until 
now, not been described. Indeed, although some 
pro-inflammatory cytokines are known to increase 
expression of ACKR2 (although notably not the 
psoriasis-associated cytokine IL17; 16,24), little is 
known about the molecular mechanisms that 
control atypical chemokine receptor expression. 
Here we identify microRNAs that are both 
differentially expressed in psoriasis and predicted 
to target the ACKR2 3’-UTR. Experimental 
evidence is provided that miR-146 and miR-10 
bind directly to the ACKR2 3’-UTR, and lead to a 
downregulation of ACKR2 at transcript and 
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protein level in keratinocytes (KC) and lymphatic 
endothelial cells (LEC) respectively. 
It is notable that we see, at best, a 50% 
reduction in luciferase activity, or ACKR2 
transcript levels, in cells transfected with miR-146 
species. It is widely accepted that this level of 
transcript knockdown represents a typical response 
to miR-mediated suppression and that more 
extensive depletion of target mRNA levels is not 
commonly seen(35,36).  
We have previously shown that mild 
trauma (tape-stripping, which induces a mild 
degree of epidermal damage and tensile stress) to 
uninvolved psoriatic skin leads to rapid 
transcriptional down-regulation of ACKR2 which, 
we propose, allows chemokine-dependent 
inflammation to become established and 
contributes to the Koebner phenomenon and the 
development of plaques(16). The Koebner 
phenomenon is reported in psoriasis, as well as a 
range of other skin diseases, whereby skin trauma 
(for example scratching and tape-stripping) 
triggers the appearance of the underlying disease 
at those sites(20). However, tape stripping induces 
several types of damage to skin, including 
disruption of skin barrier function, as well as 
tensile stress during the rapid removal of the tape 
adherent to skin. Additionally, it is notably that 
psoriatic plaques have a predilection for areas 
undergoing repeated tension, e.g. elbows, knees, 
skin folds. To specifically mimic tensile trauma to 
keratinocytes in vitro, we used a cell-flexing 
device to induce tensile stretch across the length of 
the keratinocytes. Flexing of resting keratinocytes, 
that express very low ACKR2 levels, did not alter 
transcript levels. In comparison, flexing of 
keratinocytes pre-treated with conditioned medium 
from activated human T-cells significantly 
reduced elevated ACKR2 expression. This was 
also seen with stretching of IFNJ-treated 
keratinocytes. Together our results demonstrate 
that, while keratinocyte trauma does not alter 
ACKR2 expression under ‘resting’ conditions, it 
does nonetheless significantly reduce T-cell 
induced ACKR2 expression levels, thus 
mimicking what is seen in uninvolved human 
psoriatic skin upon trauma(16). Despite being well 
described, a mechanism for the Koebner 
phenomenon (Koebnerisation) has not been 
elucidated. Our findings presented here provide a 
novel molecular mechanism by which 
Koebnerisation might be induced in unaffected 
psoriatic skin, potentially through the upregulation 
of miR-146 and its interaction with ACKR2 
transcripts. To this end we defined the impact of 
flexing on miR-146 expression in T-cell 
supernatant treated keratinocytes. These analyses 
revealed a marked induction of miR-146a (and to a 
lesser extent miR-146b) in flexed, compared to 
static, T-cell treated keratinocytes. These data 
therefore indicate that increased expression of 
miR-146 following mild trauma to keratinocytes, 
and in psoriatic plaques, is able to counteract the 
inductive effects of activated T-cell products on 
ACKR2 expression. Thus, these findings also 
provide a plausible mechanistic explanation for the 
Koebner phenomenon in inflammatory skin 
diseases such as psoriasis and may have wider 
implications for non-cutaneous inflammatory 
diseases in which tensile strength is a contributing 
factor e.g. rheumatoid arthritis.  
 
Experimental Procedures 
 
microRNA in silico selection: 
MicroRNAs that were predicted to bind to the 3’-
untranslated region (UTR) of ACKR2 were 
identified using TargetScan version 6.2 
(www.targetscan.org). MicroRNAs with the 
highest likelihood of binding the ACKR2 3’-UTR 
(as indicated by the total context, CT score) and 
that were concurrently identified as being 
upregulated in psoriatic plaques in humans were 
selected for further study(27,37).  
 
Cell culture: Primary healthy human 
keratinocytes (KC) and lymphatic endothelial cells 
(LEC) were purchased (PromoCell, Heidelberg, 
Germany) and cultured as per the manufacturer’s 
instructions in KCGM2 and ECMV2 medium 
respectively (PromoCell, Heidelberg, Germany). 
All in vitro experimental work was conducted at 
Passage 3-4, at 70% confluence (averaged across 
the vessel). All cells were maintained at 37°C in a 
humidified tissue culture incubator with 5% CO2. 
Cells were grown in the presence of 1% 
Penicillin/Streptomycin (Sigma, UK) and 0.1% 
Gentamicin solution (50mg/ml, Sigma, UK). 
Experiments in primary human cells were 
generally repeated using cells from at least 2 
separate cell donors. HEK293 cell lines were 
kindly donated by Dr K. Hewit, and were grown in 
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DMEM (Sigma, UK) to which was added 50ml 
Foetal Calf Serum and 5ml L-glutamine per 
500mls (Sigma, UK). Data representative of 2 or 
more independent experiments, with a minimum 
of 3 replicates for each experiment. 
 
microRNA transfection of cells:Cells 
were transfected with Lipofectamine RNAiMax as 
per manufacturer’s instructions (ThermoFisher, 
UK). Cell culture medium was changed to 
antibiotic free equivalents 24h prior to 
transfection, and maintained antibiotic free 
throughout the transfection process.  Cells were 
transfected at 70% confluence. microRNAs, 
scrambled microRNA control and miR inhibitors 
(miRvana, ThermoFisher, UK) were transfected as 
per the manufacturer’s in 50ȝl Opti-MEM 
(reduced serum medium, ThermoFisher, UK), 
Transfection was allowed to occur at 37° for 24 
hours before the cells were lysed (or the medium 
was changed for prolonged incubation). At this 
concentration, the microRNAs had no detectable 
effect on cell viability. 
 
RNA extractions and Quantitative 
PCR: RNA was extracted and purified on RNeasy 
Micro columns, or miRneasy columns (Qiagen, 
UK) with on-column DNAse digestion (DNase, 
Qiagen, UK) as per manufacturer’s instructions. 
Whole tissue samples were homogenized in Qiazol 
with stainless steel beads using a TissueLyser LT 
(Qiagen, UK). 1 Pg total RNA was reverse 
transcribed using nanoscript RT or RT2 kits as per 
manufacturer’s instructions (PrimerDesign, UK). 
For samples intended for microRNA QPCR, 
440ng total RNA was reverse transcribed using 
miScript II RT kit as per manufacturer’s 
instructions (Qiagen, UK). Samples were diluted 
1:5 in nuclease-free water prior to being used as a 
template for QPCR. Gene transcripts were 
quantified by quantitative PCR analysis using 
Perfecta SYBR Green master mix as per 
manufacturer’s instructions (Quanta, UK). 
Samples were analyzed in quadruplicate on a 384-
well Applied Biosystems 7900HT platform 
(LifeTechnologies). ACKR2 transcript levels were 
normalized to human TATA Binding Protein 
(TBP). The sequences for the Q-PCR primers were 
as previously reported(16,31,38) except for 
TRAF6 and IRAK1. For samples intended for 
microRNA quantification, QPCR was performed 
using the miScript SYBR Green PCR kit, with 
primers for miR-146a and 146b normalised to 
RNU6B expression (all Qiagen UK, and as per 
manufacturer’s instructions), and analyzed on a 
384-well Applied Biosystems 7900HT (Life 
Technologies). Results for microRNA were 
analysed according to the ǻǻ-method, rather than 
semi-absolute methods as used for mRNA. 
 
Luciferase microRNA assay: The 3’-
untranslated region (UTR) of ACKR2 was cloned 
into the dual luciferase system containing the 
pmiRGLO vector (Promega, UK). The 3’-UTR 
region was sequenced to ensure putative 
microRNA binding sites were intact (Eurofins, 
UK).  
The plasmid was transfected into HEK293 
cells and stable transfectants generated through 
selection with 0.8mg/ml G418 (Promega, UK). 
Non-ACKR2 containing pmiR vector was 
transfected as a control. HEK293 cells were 
donated by Dr K Hewit, and grown in DMEM 
(Sigma, UK) with added penicillin/streptomycin as 
per above. Several clones were identified for 
further testing, and two of these clones were 
transfected with the relevant microRNAs/controls, 
cells lysed and Firefly luciferase activity 
normalised to Renilla luciferase (as per 
manufacturer’s instructions, Promega, UK). pmiR 
containing HEK293 cells (i.e. with no ACKR2 3’-
UTR) and native HEK293 cells were used as 
controls in the assay, that was repeated using two 
separate HEK293 clones.  
 
Fluorescent immunocytochemistry: 
Cells were cultured in 4-well chamber-slides 
(ThermoScientific Nunc, or BD Falcon). Slides 
were washed in Phosphate Buffered Saline (PBS) 
without calcium (Sigma) and fixed with 100% 
methanol. Slides were washed and blocked with 
20% normal horse serum in PBS with 0.05% 
Tween (Sigma), followed by an Avidin/Biotin 
block. Slides were stained for ACKR2 using 
Sigma Prestige anti-human ACKR2 IgG antibody 
(Sigma, UK) raised in rabbit in 2.5% normal 
human serum and 2.5% horse serum (Vector 
Laboratories, UK) in PBS-Tween (PBST), 
overnight at 4oC and then stained with a secondary 
antibody (biotinylated anti-rabbit IgG raised in 
goat, with 5% human serum). Slides were washed, 
incubated with Avidin-D fluorochrome conjugated 
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with FITC (Vector Laboratories, UK) and 
mounted with Vectamount containing DAPI 
(Vector Laboratories) prior to visualisation 
through confocal microscopy (LSM510, Zeiss). 
 
 
Tensile stress of keratinocytes: For 
FlexCell experiments, primary human 
keratinocytes were grown in BioFlex 6-well plates 
pre-coated with Collagen I (FlexCell International, 
USA) for KC, or plain BioFlex 6-well plates 
coated with Fibronectin overnight prior to use 
(Sigma, UK) for LEC. Cells were subjected to 
tensile stress at 15% effective stretch, 0.8Hz, ½ 
sine waveform using the FlexCell FX-5000 Cell 
Tension System (FlexCell International). Cells 
were stretched for 12 hours, and rested for a 
further 12 hours, prior to lysis. All cells were 
grown and subjected to tension in a humidified 
incubator at 37°C with 5% CO2. 
 
T-cell isolation and stimulation: Human 
T-cells were grown from CD14-depleted human 
buffy coats from healthy donors, and stimulated 
with Concanavalin A (5ng/ml, Sigma, UK), and 
grown in RPMI (LifeTechnologies, UK) with 5% 
human AB serum and gentamicin (Sigma) in the 
presence of IL-2 (20 units/ml, Peprotech, UK) 
from day 4. Cells were purified on Ficoll-Paque 
after 8 days (GE Healthcare) and grown in the 
presence of IL-2 alone for 4 days, before being 
activated using CD2/CD3/CD28 beads as per 
manufacturer’s instructions at a 1:2 bead:cell ratio 
(Miltenyi Biotec, UK) for 24 hours prior to the 
activated supernatant being removed for 
downstream applications. Where T-cell 
supernatant was to be used for KC/LEC 
stimulation, T-cells were grown in serum-free 
keratinocyte medium KCGM2 or ECMV2 with 
added supplements during the 24-hour activation 
period (PromoCell, Germany). T-cells used for 
migration assays were similarly activated albeit at 
a 1:4 bead:cell ratio for 48 hours prior to use.  
 
Statistical analyses: Student’s t-test, One-
way ANOVA, two-way ANOVA and correlation 
tests were performed in Prism Version 7.0 
(GraphPad Software Inc), with multiple 
comparison tests as appropriate. P<0.05 was 
deemed significant. All data are n3 and are 
representative of at least 2 independent 
experiments, and given as Mean ± SEM unless 
otherwise stated. 
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Figure legends 
 
Figure 1. In silico analyses identified several psoriasis-associated of putative ACKR2-3’-UTR 
interacting microRNAs.  
(a) Summary of microRNAs predicted to bind the ACKR2 3’-UTR with associated microRNA-specific 
data from previous psoriasis publications. The 10 microRNAs most likely to target ACKR2 are included 
in the diagram, with relevant findings in two papers given in the right hand column; miR-10, miR-146 
and miR-203 were all differentially regulated in psoriasis(27,37).  
(b) Three microRNAs (miR-10, miR-146 and miR-203) are both predicted to bind the ACKR2 3’-UTR 
and are differentially expressed in psoriasis. Diagrammatic representation of microRNAs that are 
predicted to bind the ACKR2 3’-UTR in silico, and that have been shown to be differentially expressed in 
psoriasis by microarray studies. 
 
Figure 2. miR-146 and miR-10 transfection reduced AKCR2 transcripts in KC and LECs 
respectively.  
(a) Absolute quantification of IRAK/TRAF6 mRNA (previously validated miR-146b targets) in primary 
healthy human keratinocytes that were stimulated with 100ng/ml of human recombinant IFNJ prior to 
transfection.  
(b) Absolute quantification of ACKR2 transcripts following transfection of KC with; (i) miR-146b; (ii) 
miR-10; (iii) miR-203.  
(c) Absolute quantification of ACKR2 transcripts following transfection of KC with miR-146a and miR-
146b. 
(d) Absolute quantification of ACKR2 transcripts following transfection of LECs with; (i) miR-10; (ii) 
miR-146b; and (iii) miR-203. 
In all cases, cells were transfected for 24 hours and left for a further 24 hours prior to lysis and RNA 
extraction. microRNAs added at 10nM, control is scrambled microRNA.  
Representative experiments conducted in cells from various cell donors. Significance was assessed using 
Student's t-test * P<0.05, ** P<0.01, except for (d) where significance was assessed using one-way 
ANOVA with Tukey’s post-test. * P<0.05, ** P<0.01, *** P<0.005 
 
Figure 3. miR-146b and miR-10b functionally interact with the ACKR2 3’-UTR. 
(a) miR-146b can be successfully transfected into HEK293 cells. Absolute quantification of IRAK1 
mRNA as assessed by QPCR in HEK293 cells following transfection with miR-146b as compared to 
scrambled control. 
(b) ACKR2 3’-UTR was cloned into the downstream UTR of a firefly luciferase reporter and interaction 
with transfected miRs determined (bioluminescence inversely proportional to microRNA 3’-UTR 
binding) and normalised to Renilla luciferase. Results are representative from two different luciferase 
expressing HEK293 clones, following transfection with miR-10b and miR-146b (singly and in 
combination) and scrambled miR control. Statistics: one-way ANOVA. * P<0.05, ** P<0.01, *** 
P<0.005, **** P<0.0001 
 
Figure 4. Transfection of KC with miR-146b reduced cytoplasmic ACKR2 protein distribution. 
(a) Representative bright-field image of KC grown as confluent monolayer 
(b) Representative immunofluorescence of KC grown as confluent monolayers, stained with isotype 
control antibody.  
(c,d) Representative immunofluorescence microscopy images of confluent monolayers of KC 48 hours 
after transfection with (c) scrambled miR control or (d) miR-146b.  
 
Figure 5. Transfection of LEC with miR-10 reduced ACKR2 protein expression throughout the 
cytoplasm. 
(a) Representative bright-field image of LEC grown as confluent monolayer 
microRNA regulation of ACKR2 expression

13

(b) Representative immunofluorescence of LEC grown as confluent monolayers, stained with isotype 
control antibody.  
(c,d) Representative immunofluorescence microscopy images of confluent monolayers of LEC 48 hours 
after transfection with (c) scrambled miR control or (d) miR-10. White arrows indicate asymmetric 
distribution of ACKR2.  
  
Figure 6. Effect of tensile stress on ACKR2 expression by primary human keratinocytes (KC). 
(a-c) Absolute quantification of ACKR2 mRNA, normalised to TBP in keratinocytes;  
(a) Healthy human primary KC that remained static, or were subjected to tensile stress (flexed) at 0.8Hz 
for 12h, and then allowed to rest for 12h prior to cell lysis and RNA extraction. 
(b) Healthy human primary KC that remained static, or were subjected to tensile stress (flexed) at 0.8Hz 
for 12h, and then allowed to rest for 12h prior to cell lysis and RNA extraction. KC were pre-treated with 
either 1) tissue culture supernatant from activated human T-cells (1:8 dilution in fresh medium), 2) 
100ng/ml recombinant human IFNȖ, or 3) tissue culture supernatant from activated human T-cells plus 
neutralising anti-IFNȖ antibodies, overnight prior to flexing at 0.8Hz for 12 hours. Black bars; non-flexed 
static controls, grey bars flexed cells. Significance was assessed using One-way ANOVA. 
(c) Treatment of healthy primary LEC overnight with tissue culture supernatant from activated human T-
cells (diluted 1:8 with fresh medium) prior to flexing. 
(d,e) Effect of tensile stress on miR-146 expression in inflamed keratinocytes. Fold change in miR-146a 
and miR-146b expression as assessed by QPCR, and normalised to scrambled miR treated static KCs. KC 
were treated for 16 hours with either; (d) tissue culture supernatant from activated human T-cells (1:8 
dilution in fresh medium); or (e) recombinant IFN-J at 100ng/ml; prior to flexing at 0.8Hz for 12hours. 
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miR 
(broadly conserved  
among vertebrates) 
Total  
Context 
Score 
 
regulation in psoriasis 
miR-10abc/10a-5p 
 
-0.57  miR-10b 1.32-fold up-regulated in PN1 
miR-10a 0.67-fold down-regulated in 
PP2 
miR-490-3p 
 
-0.29 n/a
 
 
miR-146ac/146b-5p 
 
-0.26 miR-146a 3.10-fold upregulated in PP, 
miR-146b-59 up-regulated 2.73-fold[Q] 
miR-146a 3.30-fold up-regulated in PP2 
miR-146b up-regulated 3.31-fold in PP2 
miR-203 
 
-0.19 2.02-fold up-regulated in PP1
5.86-fold up-regulated in PP2 
 
miR-210 
 
-0.15 n/a
 
 
miR-24/24ab/24-3p 
 
-0.15 1.51-fold and 1.41 up-regulated in PP 
and PN respectively1 
 
miR-122/122a/1352 
 
-0.13 n/a
 
 
miR-103a/107/107ab 
 
-0.13 1.04-fold up-regulated in PP1
 
 
miR-145 
 
-0.10 n/a
 
 
miR-375 
 
-0.09 n/a
 
 
PP – psoriatic lesion (plaque) PN – normal (clinically unaffected) psoriatic skin 
 
 
 
 
 
 
 
  
a
miR-10
miR-146
miR-203
16 miRs (broadly 
conserved in 
vertebrates)  
predicted to bind 
to the ACKR2 3’-
UTR. 
(TargetScan 
v6.2)
47 miR 
differentially 
expressed in PP 
versus NN (Zibert 
et al. J Derm Sci 
2010)
29 miR 
differentially 
expressed in PP 
versus NN 
(Sonkoly et al. J 
PLOS One 2007)
b
Figure 1
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